Showing 1 - 10 of 4,515
. Although we find that direct reforms improve medical productivity primarily by reducing malpractice claims rates and …
Persistent link: https://www.econbiz.de/10012471241
little or no incremental value. In this paper, we draw on macroeconomic models of diffusion and productivity to better … differences in the propensity to adopt technology can lead to wide and persistent productivity differences across countries -- or … productivity, and swamp the impact of traditional factor inputs. Holding technology constant, the marginal gains from spending on …
Persistent link: https://www.econbiz.de/10012463783
As countries reform their patent laws to be in compliance with the Trade Related Intellectual Property Rights Agreement …, an important question is how increased patent protection will affect drug prices in low-income countries. Using …
Persistent link: https://www.econbiz.de/10012461408
Alan Garber and Jonathan Skinner (2008) famously conjectured that the US health care system was "uniquely inefficient" relative to other countries. We test this idea using cross-country data on prescription drug sales newly linked with an arguably objective measure of relative therapeutic...
Persistent link: https://www.econbiz.de/10012455612
Beginning in the mid-2000s, the incidence of drug shortages rose, especially for generic injectable drugs such as anesthetics and chemotherapy treatments. We examine whether reimbursement changes contributed to the shortages, focusing on a reduction in Medicare Part B reimbursement to providers...
Persistent link: https://www.econbiz.de/10012460672
We study the effects of competition by state-owned firms, leveraging the decentralized entry of public pharmacies to local markets in Chile. Public pharmacies sell the same drugs at a third of private pharmacy prices, because of stronger upstream bargaining and market power in the private...
Persistent link: https://www.econbiz.de/10013477271
models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …
Persistent link: https://www.econbiz.de/10012469960
We explore the effects of recent Medicaid expansions on Medicaid-financed prescriptions for evidence-based smoking cessation medications. We estimate differences-in-differences models using administrative data on the universe of prescription medications sold in retail and online pharmacies for...
Persistent link: https://www.econbiz.de/10012455231
Branded pharmaceutical manufacturers frequently offer "copay coupons'" that insulate consumers from cost-sharing, thereby undermining insurers' ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and 2010. To...
Persistent link: https://www.econbiz.de/10012455935
A large literature in empirical public finance relies on "bunching" to identify a behavioral response to non-linear incentives and to translate this response into an economic object to be used counterfactually. We conduct this type of analysis in the context of prescription drug insurance for...
Persistent link: https://www.econbiz.de/10012456308